Rau KM, et al. - In this retrospective analysis, researchers judged if eribulin has a therapeutic role in metastatic breast cancer. They analyzed 449 cases treated with eribulin for locally advanced or metastatic breast cancer between March 2014 and June 2017 at 14 hospitals in Taiwan. The survival rate at 24 months was 57.2%. A significantly better objective response rate was reported for patients’ tumors with the luminal A subtype. In Kaplan–Meier analysis, factors that showed significant association with longer time to treatment failure (TTF) included hormone receptor positivity, luminal A subtype, receipt of eribulin as the first to third line therapy, and metastasis to fewer than four organs. Overall, in Taiwanese women vs Western women, better efficacy and fewer adverse events (especially neutropenia) of eribulin were observed.